الفهرس 
NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITISOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is a worldwide epidemic with global prevalence estimated at 25%. Although NAFLD is usually associated with obesity, patients who are not obese can also present with NAFLD; this is known as “lean NAFLD.” Lean NAFLD is defined as NAFLD that develops in patients with a body mass index (BMI) <25 kg/m2. The prevalence of lean NAFLD varies from 7% in the United States to as high as 19% in Asia . Unfortunately, being lean (not overweight) does not necessarily lead to better health.
Aim of the study Determining the correlation of Fib-4 score and NAFL diagnosed by liver biopsy in lean Egyptian patients
Patients and Methods : This study had been carried out on 30 subjects, age range above 18 years old, with BMI (18.5-24.9) selected from transplantation donor outpatient clinic at Ain shams university specialized hospital in Cairo after informed consent were taken from the patients
Subjects were divided as follow: group I: 15 adult patients with NAFLD. group II: 15 adult patient with normal liver biopsy who will be educated about lean NAFLD and how to prevent it.
Results : In the current study we concluded that FIB-4 score is not significant with degree of fibrosis while it has a negative correlation with steatosis assessed by biopsy. FIB-4 failed to discriminate advanced fibrosis. Conversely,it showed acceptable diagnostic performances in exclusion of advanced fibrosis in overweight, obese, and severely obese patients in other studies. (FATIH et al., 2020)
Conclusion : FIB-4 failed to discriminate advanced fibrosis. Conversely,it showed acceptable diagnostic performances in exclusion of advanced fibrosis in overweight, obese, and severely obese patients. FIB-4 was able to exclude advanced fibrosis with the highest diagnostic accuracy in the subgroup of overweight patients . so fib 4 score can’t be used as a marker of fibrosis nor steatosis in lean NAFLD patients but more like a prognostic value